Gennex Laboratories Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Gennex Laboratories Ltd. on BSE

Load latest

Gennex Laboratories Ltd.

14 Feb 2025

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Statement Of Deviation Or Variation In The Use Of Proceeds …

BSE India

Pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of the proceeds during the quarter ended December 31, 2024, from the objects stated in the letter of offer for the funds raised by the Company. A Statement of Deviation stating that there is no deviation or variation in the utilization of proceeds , duly reviewed by the Audit Committee, is attached. We request you take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

14 Feb 2025

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Resignation of Director

BSE India

With reference to above captioned subject, this is to inform you that Mr. Mohammed Khaleequr Rahman, Non-Executive Non-Independent Director has tendered his resignation from the Board as Director of the Company due to some personal reasons and other per-occupations with immediate effect. The resignation letter has been placed before the Board of Directors in the Board Meeting held today i.e. February 14, 2025 for its consideration and formal acceptance in accordance with the aforementioned regulation. The relevant details of the captioned resignation, as per the requirement of Regulation 30 of SEBI (LODR) Regulations, 2015, read with SEBI Circular # 2023/123 dated July 13, 2013 are given in the enclosed Annexure A. The intimation is also being uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

10 Feb 2025, 04:19PM

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

With reference to our intimation dated November 14, 2024 regarding appointment of Chief Financial Officer and your query vide email dated January 20, 2025 to submit reasons for delay for not submitting the details of appointment of Chief Financial Officer within 12 hours from the effective date of appointment i.e. November 12, 2024, we hereby submit our explanation. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

10 Feb 2025, 03:30PM

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of SEBI (LODR), 2015, please find enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company Scheduled to be held on Friday, February 14, 2025 for adoption of Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Nine months Ended December 31, 2024 along with the Limited Review Report of the Statutory Auditors of the Company. Notice had been published in both Business Standard and Saksham (Local) on February 04, 2025. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

03 Feb 2025

12.07

-3.98%

Board Meeting

GENNEX LABORATORIES LTD. - 531739 - Board Meeting Intimation for Unaudited Financial Results For The Quarter …

BSE India

GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2024; 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Nine Months ended December 31, 2024; 3. Other Business items.

pdf

Gennex Laboratories Ltd.

29 Jan 2025

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the Certificate received from the M/s R&D Infotech Pvt. Limited, Registrar and Transfer Agent of the Company for the quarter ended December 31, 2024. We request you to take the above information on record and acknowledge the receipt of the same.

pdf

Gennex Laboratories Ltd.

27 Dec 2024

12.07

-3.98%

SAST

GENNEX LABORATORIES LTD. - 531739 - Closure of Trading Window

BSE India

Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company''s Code of Conduct for Regulation, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the securities of the Company shall remained closed from January 01, 2025 till 48 hours after the public announcement through Board of Directors in their meeting held for announcing the Unaudited Financial Results for the Third Quarter and Nine months ended on December 31, 2024 along with other matters for which trading window is required to be closed. The Board Meeting date to approve the Unaudited Financial Results of the Company for the third quarter and none months ended December 31, 2024 will be informed in due course. All Promoters / Designated / Connected persons are advised not to trade in the securities of the Company during the aforesaid period of closure of trading window. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

16 Nov 2024

12.07

-3.98%

Company Update

GENNEX LABORATORIES LTD. - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of SEBI (LODR), 2015, please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30, 2024 announced by the Board of Directors in its meeting held on Thursday, November 14, 2024. Financial Results had been published in both Business Standard (English) and Saksham (Telugu - Local) on Saturday, November 16, 2024. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

14 Nov 2024

12.07

-3.98%

Result

GENNEX LABORATORIES LTD. - 531739 - Financial Results For The Quarter And Half Year Ended September …

BSE India

In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2024. 2. Limited Review Reports from the Statutory Auditors on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2024 (annexed herewith). We hereby submit that the Board meeting had commenced at 4.00 PM and concluded at 11.00 PM. The intimation is also being uploaded at Company website: www.gennexlab.com We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

14 Nov 2024

12.07

-3.98%

Board Meeting

GENNEX LABORATORIES LTD. - 531739 - Board Meeting Outcome for Outcome Of The Board Meeting Of …

BSE India

In just Concluded Meeting of Board of Directors the Board approved and considered the following items: 1. Unaudited Financial Statements for the Quarter and Half year ended September 30, 2024 2. Limited Review Reports from the Statutory Auditors 3. Reconstitution of Board Committees 4. Appointment of Chief Financial Officer 5. Other Items We hereby submit that the Board Meeting had commenced at 04.00 PM and concluded at 11.00 PM. The intimation is also uploaded at Company website: www.gennexlab.com We request you to take the above information on record and acknowledge receipt of the same.

pdf

Is Gennex Laboratories Ltd. worth buying?

126 Votes:

Buy 83.33%

Sell 6.35%

Hold 10.32%